Giannopoulos et al. compared the parameters of surgical invasiveness between PDS-CT (n = 29) and NACT (n = 35) in the treatment of stage IIIC/IV ovarian cancer. [21] Patients treated with NACT ...

Neoadjuvant chemotherapy for advanced ovarian cancer was initially administered as an alternative treatment for patients not suitable for primary debulking surgery (PDS) because of unresectable ...

Avelumab is under clinical development by Merck and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) ...

The addition of camrelizumab to neoadjuvant chemotherapy improves pathological complete response for patients with early or locally advanced triple-negative breast cancer, according to a study ...

20 December 2023 Recruitment is now open for our Cancer faculty. Full details and the expertise required, can be found on https://www.nice.org.uk/get-involved/our ...

Citation: Clinical trial finds adding camrelizumab to neoadjuvant chemo beneficial in triple-negative breast cancer (2024, December 16) retrieved 30 December 2024 from https://medicalxpress.com ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with ...

“We understand the significant challenges that ovarian cancer presents to women and their families, especially women with advanced late-stage disease who are newly diagnosed, and that there is a ...